Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Kezar Life Sciences (KZR) stocks in Canada

Learn how to easily invest in Kezar Life Sciences stocks.

Kezar Life Sciences is a biotechnology business based in the US. Kezar Life Sciences stocks (KZR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.44 – a decrease of 4.84% over the previous week. Kezar Life Sciences employs 47 staff and has a market cap (total outstanding stock value) of $758.6 million.

How to buy shares in Kezar Life Sciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KZR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Kezar Life Sciences stock price (NASDAQ:KZR)

Use our graph to track the performance of KZR stocks over time.

Kezar Life Sciences shares at a glance

Information last updated 2022-01-18.
Latest market close$13.18
52-week range$4.61 - $17.28
50-day moving average $13.25
200-day moving average $8.21
Wall St. target price$20.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.00

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Kezar Life Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Kezar Life Sciences price performance over time

Historical closes compared with the close of $13.18 from 2022-01-18

1 week (2022-01-12) -4.84%
1 month (2021-12-16) -4.70%
3 months (2021-10-19) 49.77%
6 months (2021-07-19) 150.09%
1 year (2021-01-19) 143.17%
2 years (2020-01-17) 303.06%
3 years (2019-01-18) 20.57
5 years (2017-01-15) N/A

Kezar Life Sciences financials

Gross profit TTM $0
Return on assets TTM -22.09%
Return on equity TTM -38.07%
Profit margin 0%
Book value $2.46
Market capitalisation $758.6 million

TTM: trailing 12 months

Kezar Life Sciences share dividends

We're not expecting Kezar Life Sciences to pay a dividend over the next 12 months.

Kezar Life Sciences share price volatility

Over the last 12 months, Kezar Life Sciences's shares have ranged in value from as little as $4.61 up to $17.28. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kezar Life Sciences's is 0.1657. This would suggest that Kezar Life Sciences's shares are less volatile than average (for this exchange).

How has Coronavirus impacted Kezar Life Sciences's stock price?

Since the stock market crash in March caused by coronavirus, Kezar Life Sciences's stock price has had significant positive movement.

Its last market close was $13.18, which is 59.94% up on its pre-crash value of $5.28 and 504.59% up on the lowest point reached during the March crash when the stocks fell as low as $2.18.

If you had bought $1,000 worth of Kezar Life Sciences stocks at the start of February 2020, those stocks would have been worth $1,443.35 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $4,265.31.

Kezar Life Sciences overview

Kezar Life Sciences, Inc. , a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California. .

Stocks similar to Kezar Life Sciences

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site